Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Directorate Changes

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, announces today that Nikolas Sofronis and Russell Barry Gibbs have resigned as directors of the Company with effect from 31 December 2008..

Commenting on the resignations, Steve Harris, Chairman of Cyprotex said:

"Both Nikolas and Russell have made significant contributions to the development of Cyprotex over the years for which we are extremely grateful. I thank them on behalf of the Company and wish them well in the future. Cyprotex is actively seeking candidates for the Board vacancies created by their resignations."

For further information:

Cyprotex PLC
Dr Anthony Baxter, CEO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited:
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires:
Pelham PR

Simon Miller
Tel: +44 (0)20 743 6670
simon.miller@pelhampr.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close